Patent · US Active

Anti-GM-CSF antibodies

US9751939B2 · kind B2 · utility

0Cited by

5References

5Claims

0Family size

Assignee

MORPHOSYS AG · DE

Inventors

Stefan Steidl · Munich, DE
Elisabeth Thomassen-Wolf · Birkenfeld, DE

Key dates

Filing date	Sep 16, 2010
Grant date	Sep 5, 2017
Priority date	—
Expiry date	Feb 23, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.